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Abstract
The first goal of this study was to measure the oxidative stress (OS) and relate it to lipoprotein variables in 35 renal patients
before dialysis (CKD), 37 on hemodialysis (HD) and 63 healthy subjects. The method for OS was based on the ratio of
cholesteryl esters (CE) containing C18/C16 fatty acids (R2) measured by gas chromatography (GC) which is a simple, direct,
rapid and reliable procedure. The second goal was to investigate and identify a triacylglycerol peak on GC, referred to as
TG48 (48 represents the sum of the three fatty acids carbon chain lengths) which was markedly increased in renal patients
compared to healthy controls. We measured TG48 in patients and controls. Mass spectrometry (MS) and MS twice in tandem
were used to analyze the fatty acid composition of TG48. MS showed that TG48 was abundant in saturated fatty acids (SFAs)
that were known for their pro-inflammatory property. TG48 was significantly and inversely correlated with OS. Renal
patients were characterized by higher OS and inflammation than healthy subjects. Inflammation correlated strongly with
TG, VLDL-cholesterol, apolipoprotein (apo) C-III and apoC-III bound to apoB-containing lipoproteins, but not with either
total cholesterol or LDL-cholesterol. In conclusion, we have discovered a new inflammatory factor, TG48. It is characterized
with TG rich in saturated fatty acids. Renal patients have increased TG48 than healthy controls.
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Introduction
A progressive loss of renal function is associated with a markedly
increased risk for cardiovascular disease (CVD) [1]. Among non-
traditional risk factors, increased oxidative stress (OS) and
inflammation have emerged as potentially significant contributors
to the progression of kidney dysfunction and its cardiovascular
consequences. Although a number of studies have shown increased
OS and inflammation in renal patients [2–12], no publication has
demonstrated the relationship between OS/inflammation and
plasma apolipoproteins (apo) and lipoproteins (Lp), including the
well established risk factors for CVD, such as triacylglycerols (TG)
and apoC-III. Since the relationship between OS/inflammation
and CVD in renal patients is not well understood, the first aim of
this study was to investigate the possible relationship between OS/
inflammation and lipoprotein variables already known to be
related to CVD with special emphasis on apoC-III, which has
recently been shown to be a link between inflammation and
atherogenesis [13]. The present study was performed on patients
undergoing haemodialysis (HD) and on patients before dialysis
(CKD), using a simple cholesteryl ester (CE) ratio method on gas
chromatography (GC) for OS [14]. Interestingly, during the
measurement of OS with GC, we found marked differences
between renal patients and healthy subjects regarding a TG
species, named TG48 (i.e. the sum of the 3 carbon chain lengths of
fatty acids in TG equals to 48) which was absent or undetectable in
healthy young normolipidemic subjects but markedly increased in
renal patients. We wondered what the significance of TG48 is in
renal disease and what types of fatty acids are present in TG48.
Thus, the second aim of this study was to investigate the TG48, i.e.
to measure TG48 with GC in renal patients and healthy subjects,
and to identify the TG48 components using mass spectrometry
(MS) and MS/MS.
Materials and Methods
Patients and Controls
Seventy two non-diabetic adult patients (46 men and 26 women)
participated in the study. The patients’ mean age was 61613
(range 27–84) years. Patients were recruited from the Department
of Nephrology, Sahlgrenska University Hospital, Go ¨teborg,
Sweden, and collaborating hospitals in Western Sweden.
There were 35 patients (23 men and 12 women) with varying
degrees of renal functional impairment before dialysis (CKD stages
3–5). In these patients, the mean glomerular filtration rate (GFR)
was 26.3 mL/min/1.73 BSA (body surface area), with a range
from 9 to 53. Patients were treated with antihypertensive agents,
angiotensin converting enzyme (ACE) and by diuretics and
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severely reduced renal function (GFR ,20 mL/min) were advised
to consume a protein reduced diet (0.6–0.8 g protein/kg BW/
24 h) for the treatment of symptoms of renal insufficiency.
Thirty seven patients (23 men and 14 women) were treated with
chronic haemodialysis (HD). Haemodialysis was performed either
with conventional haemodialysis or with haemodiafiltration using
standard procedures and equipment. All patients were dialyzed
with bicarbonate-containing dialysis fluid. In the majority of cases
low molecular weight heparin was added as an anticoagulant.
Patients were treated three times weekly for four to five hours per
session with antihypertensive drugs, diuretics, calcium supple-
ments, phosphate binders, intravenous iron and erythropoietin, as
appropriate. The target hemoglobin levels were 120–130 g/L.
Patients on steroid treatment, lipid-lowering drugs or other
drugs that may have influenced lipoprotein metabolism, were
excluded from the study as were patients with diabetes mellitus.
Patients were not advised or monitored with respect to dietary
lipids. None of the patients received intravenous iron, vitamin D or
intravascular radiocontrast media within a week before blood
sampling. Patients were not specifically treated with larger doses of
vitamin E preparations.
Control subjects were recruited among healthy, normolipidemic
employees (30 men and 33 women) of the Sahlgrenska University
Hospital, Go ¨teborg, Sweden and Oklahoma Medical Research
Foundation, Oklahoma City, Oklahoma, USA. All studies were
conducted in accordance with the Helsinki declaration and
approved by the Ethical Committee of the Sahlgrenska University
Hospital, Go ¨teborg, Sweden. All subjects gave their written
informed consent.
Blood samples were drawn after an over-night fast and collected
into EDTA-containing tubes. In HD patients, blood was drawn
prior to heparinization for dialysis through the dialysis access.
Blood samples were then centrifuged. Preservatives containing
thimerosal and a protease inhibitor, e-amino caproic acid, were
added to a final concentration of 0.1% and 10 mM respectively,
and immediately shipped by air to Oklahoma City, Oklahoma,
USA, where analyses were performed. Glomerular filtration rate
was measured by renal or plasma clearance of either iohexol or
51Cr-EDTA, as previously described [15].
Lipid and apolipoprotein analyses
Plasma TC (Alfa Wassermann; Caldwell, NJ)) and TG (Alfa
Wassermann; Caldwell, NJ) concentrations were determined
enzymatically on Alfa Wassermann Nexct Analyzer. High-density
lipoprotein-cholesterol (HDL-C) was measured as previously
described [15]. Very low density lipoprotein cholesterol (VLDL-
C) levels were assumed to equal one fifth of the plasma TG
concentration, and low density lipoprotein-cholesterol (LDL-C)
levels were determined as described previously [15,16].
The quantitative determination of apolipoproteins (apo) was
performed by electroimmunoassays developed in our laboratory
[15,16]. The measurement of apoC-III bound to apoA-I (HDL)
and apoC-III bound to apoB-(VLDL+LDL)-containing lipopro-
teins was performed on heparin-Mn
++ supernates (apoC-III-HS)
and heparin-Mn
++ precipitate (apoC-III-HP), respectively, accord-
ing to a previously described procedure [15,16]. The apoC-III-
ratio (apoC-III-R) was calculated as apoC-III-HS/apoC-III-HP.
Measurement of oxidative stress by cholesteryl ester
ratios method
Indices of OS were measured according to the method
developed by Lee [14]. Briefly, the neutral lipids were extracted
from fresh plasma with isopropanol:heptane (7:3) containing
internal standard (I.S.) CE-butyrate (CE-C4) under argon. After
acidification with dilute H2SO4, the top heptane phase was
concentrated under N2, and the neutral lipid molecular species
were analyzed by GC as described by Kuksis et al [17] and
modified by Lee [14], using Varian Chrompack CP-3000 Gas
Chromatograph and ultra-pure helium gas as carrier for vaporized
samples. The column was CP 7592, WCOT Ulti-metal, coating
HT Simdist film thinness 0.52 mm, 10 m in length and 0.53 mm
in diameter. The initial temperature of the column, 160uC, was
increased to 380uC at a rate of 10uC per minute. The area on the
GC chromatogram for CE containing C16 fatty acyl groups was
calibrated with recrystalized cholesteryl palmitate; CE containing
C18 fatty acyl groups was calibrated with cholesteryl linoleate and
CE containing C20 fatty acyl groups with cholesteryl arachido-
nate. All primary standards were from Nu-Chek-Prep, Inc.
Elysian, MN, USA.
Cholesteryl esters with C16 fatty acyl groups are mostly
saturated fatty acids (C16:0) with a small amount of monounsat-
urated fatty acid (C16:1), which is considered not susceptible to
oxidative damage. Cholesteryl esters with C18 fatty acyl groups
are mostly C18:2 with small amounts of C18:1 and C18:0. The
C18:1 and C18:0 are resistant to oxidation while CE-C18:2 are
susceptible to oxidative damage. Cholesteryl esters with C20 fatty
acyl groups are mostly C20:3 with small amounts of C20:4 and
C20:5, which are the most sensitive to oxidative damage. Since it is
possible to separate the molecular species of CE by the number of
carbon atoms of esterified fatty acids, it is possible to calculate the
ratios CE-C20/CE-C16 (R1) and CE-C18/CE-C16 (R2) as
estimates of peroxidative damage [14]. Due to a greater loss of
polyunsaturated fatty acid esters to oxidative damage, lower CE
ratios indicate a higher OS. The method was verified with
thiobarbituric acid-reactive substances (TBARS) since both R1
and R2 are negatively correlated with TBARS (r=20.68,
p,0.0001, n=24, for R1, and r=20.62, p,0.001, n=25, for
R2) [14]. Since the sizes of CE-C18 peaks are greater than those of
CE-C20, the measurement of the former are more accurate than
those of the latter. Therefore, we have selected R2 as the marker
for OS in this study.
Measurement of TG species with gas chromatography
From the same above neutral lipid extract, TG species were
measured following CEs separations. TG48 was calibrated with
tripalmitate. TG54 was calibrated with tristearate. (All primary
standards were from Nu-Chek-Prep, Inc. Elysian, MN). Two
reference sera (from Boehringer-Mannheim Corp., Indianapolis,
IN) with known TC and TG values were also used to verify the TC
and the TG values derived from the sum of molecular species of
neutral lipids by GC. TGspecies includeTG48, TG50, TG52,TG54
and TG56 (the numbers following TG represent the sum of the 3
carbonchainlengthsoffattyacids).Occasionally,CE-C20andTG48
did not separate completely. A vertical line drawing through the
valley of the two peaks was used for separation and measurements.
These measurements were validated by re-application with smaller
amount of samples that could be separated completely.
The GC method yielded within 97–99% of known TC values
and 95–106% of known TG values. The intra-assay variations
were 3.34% for R2, 2.24% for CE, 5.64% for TG and 4.22% for
TG48. The inter-assay variations were 0.90% for R2, 4.19% for
CE, 5.3% for TG and 5.94% for TG48.
Measurement of TG48 with GC and identification of the
components of TG48 by Mass Spectrometry
For example, as demonstrated in Fig. 1A a GC chromatogram
of a young fasting healthy subject with low plasma TG showed the
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height increased (See example in Fig. 1B). For identification of
compounds occurring in TG48 peak, MS was used, following the
method of Liebisch et al. [19]. The same hexane extract (10 ml) of
plasma neutral lipids containing I.S. CE-C4 for GC analyses was
evaporated under a stream of nitrogen. The sample was then
redissolved in 50 ml of a solvent mixture of methanol and
chloroform (3:1 v:v) containing 7.5 mM ammonium acetate. This
solution was then analyzed by direct flow injection analysis using a
syringe pump at a flow rate of 5 ml/min. Bruker Daltonics Inc.
HCT ultra ion-trap mass spectrometer equipped with an
electrospray ion source was used and operated in the positive
ion mode. Samples ionized in the presence of ammonium acetate
carried an NH4
+1 ion, so the mass/charge (m/z) increased by 18
over that of the uncharged molecule. CE-C4 with +1 charge was
confirmed to have m/z 474.3 on MS. The expected m/z for
saturated TG48:0, monounsaturated TG48:1, di-unsaturated
TG48:2 and tri-unsaturated TG48:3 are shown in Table 1.
Standard tripalmitate (TG48:0 from Nu-Chek-Prep) with +1
charge was confirmed to have m/z=824.7. Standard tripalmito-
lein (TG48:3 from Nu-Chek-Prep.) with +1 charge was confirmed
to have m/z=818.7. The areas of all m/z peaks observed within
the measured mass range were calculated automatically by the
instrument software. After normalizing the areas of I.S. from all
runs, the intensities from different runs could be compared.
Identification of the fatty acids composed in TG48 by
MS/MS
The fatty acid composition of TG48 was determined by MS/
MS of ammoniated triacylglycerol (TG) ions isolated in the first
stage MS. The MS/MS data was obtained by collisional induced
disassociation at 3.5 volts of selected TG ions, essentially according
to the method of McAnoy et al. [20]. Ammoniated TG (parent)
ions at 818.6, 820.7, 822.7, and 824.7 m/z corresponding to the
m/z values of TG48:3, TG48:2, TG48:1 and TG48:0, respec-
tively, were individually fragmented, generating TG
+1 as a result
of loss of ammonia, diacylglycerols (DG) and DG fragments at
position 1,2; 2,3; and 1,3 for each TG fragmented. The fatty acids
for each TG were identified by comparison of our products to the
published m/z values for TG
+1,D G 1,2,D G 2,3, and DG1,3, [21].
When all DG and DG fragments observed by MS/MS were
accounted for, the composition of fatty acids for each TG48 was
considered completed.
Statistical methods
A two-tailed T-test with Satterthwaite adjustment was used to
identify whether there was a difference in means. A Pearson
product moment correlation was used to quantitate the relation-
ship between variables. Multiple linear regression was performed
to create a multivariate model to predict TG48 concentrations.
Data were analyzed in SAS v.9.1.3 (Cary, NC) and R v.2.5.1
(Vienna, Austria). Univariate p-values were adjusted for multi-
plicity through the Benjamini & Hochberg False Discovery Rate
(FDR) procedure [22]. A 5% FDR was considered statistically
significant.
Results
Due to its high correlation with an established OS marker,
TBARS [14], R2 was used as a valuable index of OS. The R2 and
TG48 levels for patients with CKD before dialysis and patients on
chronic maintenance haemodialysis (HD) compared to those of
normal controls are shown in Table 2. These data showed that the
R2 in CKD and HD patients were significantly lower than that of
healthy controls, thus higher OS. The data also showed that TG48
in CKD and HD patients were significantly higher than that of
healthy controls. Pearson correlations were calculated between
TG48 and R2 for each of the three groups: CKD, HD and
controls. CKD (r=20.39, p-value =0.02), and HD (r=20.41, p-
value =0.01) both had significant p-values associated with their
correlations. In contrast, controls had a non-significant p-value
(r=-0.17, p-value =0.18) which is understandable, since a large
number of controls had zero or near zero TG48 values. These
results indicated that TG48 levels were closely related to OS in
CKD and HD patients.
Table 2 also shows the lipid and apolipoprotein profiles of renal
patients and healthy controls.
The levels of TC, TG, VLDL-C, LDL-C, apoB, apoE, apoC-
III, and apoC-III-HP were significantly higher, and HDL-C were
significantly lower in CKD and HD compared to controls. The
concentrations of apoC-III-HS were significantly higher in HD
compared to controls, but not in CKD. The apoC-III-R was
significantly lower in CKD, but not in HD.
The control group is younger than the patient population.
However, analysis of the influence of age and gender shows that
the contribution of age was very small as seen in TG48 model
equation #1; therefore, this age difference is inconsequential to
our conclusions. We may calculate the age effect by placing real
numbers into this equation, assuming VLDL-C =33, an age
difference of 11 years will affect only 5–6% of the TG48 value,
while the value of TG48 in HD group is 317% higher, and TG48
in CKD group is 550% higher than controls.
BMI data was not listed in Table 2 because there were missing
data in the HD and control groups. BMI for controls was
24.163.5 (n=51) and for HD was 24.064.6 (n=23), p= not
significant (N.S.)) when compared to controls. Therefore, the
significant differences in R2 and TG48 between HD and control
cannot be due to BMI effect. BMI for CKD was 25.763.6 (n=35)
(p,0.025) compared to controls.
There was no gender difference in the HD group for BMI,
24.564.51 (n=7) for females, and 23.7664.71 (n=16) for males
with p=N.S. The BMI for females and males in CKD group was
24.8564.10 (n=12), and 26.1563.35 (n=23) respectively with p=
N.S. The BMI for females and males in controls was 22.6362.77
(n=23) and 25.3963.49 (n=30) respectively with p,0.005
between females and males. There was, as expected, a correlation
between BMIand TG, VLDL-C, apoC-III-HS,and HDL-Cbutno
correlation between BMI and R2, TG48, GFR in CKD group.
Our data showed that there were no gender differences in R2
for CKD or for HD. Nor was there a gender difference in apoC-
III-HP for CKD or HD.There was no correlation between GFR
and R2 or TG48. GFR was negatively correlated with apoC-III,
apoE, and apoC-III-HP and positively correlated with apoC-III-
R. The lack of correlation between GFR and R2 or TG48 was
probably due to narrow ranges of these values.
Correlation coefficients among TG48 and R2 and the
lipoprotein variables of controls, CKD and HD are presented in
Table 3. Among controls, TG48 moderately correlated with TG
(r=0.42, p,0.005), VLDL-C (r=0.44, p,0.005), and weakly
with apoC-III (r=0.35, p,0.025) and inversely with apoC-III-R
(r=20.30, p,0.05). R2 was weakly correlated with apoC-III
(r=-0.36, p,0.05) among all lipoprotein variables in controls.
In CKD patients, TG48 was strongly positively correlated with
TG (r=0.79, p,0.0005), and VLDL-C (r=0.78, p,0.0005),
moderately correlated with apoC-III-HP (r=0.55, p,0.005),
apoC-III (r=0.49, p,0.025) and inversely with apoC-III-R
(r=- 0.42, p,0.025). No lipoprotein variables were significantly
correlated with R2 in CKD patients (Table 3).
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VLDL-C (r=0.47, p,0.025) (Table 3). Correlations between
lipoprotein variables and R2 were not significant.
Multivariate linear regression modeling revealed that VLDL-C
and LDL-C could be combined to predict TG48 in renal patients
when adjusted for age. The data were modeled according to the
following equation:
TG48 ~{ 4:85 z 0:637   VLDL{Cm g =dL ðÞ z
0:11   Age yrs ðÞ {VLDL{C   Age   0:006{
0:022   LDL{Cm g =dL ðÞ
ð1Þ
The model explained 61.5% of the variability in TG48.
Examining the partial sums of squares revealed that VLDL-C
explained 51% of the variability while LDL-C explained only
3.3% of the variability.
Alternatively, a second model showing apoC-III-HP and apoB
with LDL-C could be combined to predict TG48 according to the
following equation:
TG48 ~ 2:9 z 0:61   apoC{III{HP mg=dL ðÞ { 0:09 
LDL{Cm g =dL ðÞ z 0:11   apoB mg=dL ðÞ
ð2Þ
This model explained 44.1% of variability in TG48. Examining
the partial sum of squares revealed that apoC-III-HP explained
29.2% of the variability in the model. Thus, apoC-III bound to
apoB-containing lipoproteins are most associated with TG48
among all lipoprotein particles. Since apoC-III-HP is a known
pro-inflammatory factor [13], and there is a direct relationship
between TG48 and apoC-III-HP, we can therefore conclude that
there is relationship between TG48 and inflammation. Note that
the equation #2 contains no age effect and no BMI effect.
Identification of the Saturated and Unsaturated Forms of
TG48 by MS
Mass spectrometry was employed for analyses of the forms of
TG48 and it showed that indeed TG48:3, TG48:2, TG48:1 and
TG48:0 species were all present in TG48 as shown in Fig. 2 and as
predicted in Table 1. MS shows that the intensities of these four
TG48 molecular species were significantly higher in CKD and
HD patients than in healthy controls (Table 4). In fact, CKD
patients had 7–13 times higher quantities of these 4 peaks and HD
patients had 3–6 times higher quantities of the same peaks than
those in healthy controls. Likewise, the relative quantities of
TG48:3 and TG48:1 species, as judged by percentage of total
TG48, were significantly different between CKD patients and
controls (Table 4). The percentage of TG48:3 was significantly
lower and TG48:1 was significantly higher in CKD patients than
in controls. The percent composition of HD patients, though
Table 1. Calculated molecular mass and m/z of saturated and
unsaturated TG48.
Names of compounds Symbols Mass
m/z with
NH4
+1
Cholesterol butyrate (I.S.) CE-C4 456.3 474.3
Tripalmitin (tripalmitylglycerol) TG48:0 806.74 824.71
1,3-Palmityl-2-palmitoleylglycerol TG48:1 804.74 822.74
Dipalmitoleyl-palmitylglycerol TG48:2 802.74 820.74
Tripalmitoleylglycerol TG48:3 800.74 818.74
doi:10.1371/journal.pone.0022360.t001
Table 2. Oxidative stress R2, lipids and apolipoproteins in
patients with kidney disease compared to controls.
Controls CKD HD
n=63 n=35 n=37
Mean ± SD Mean ± SD Mean ± SD
R2 5.1861.26 4.1860.77
a 4.4860.68
b
TG48 (mg/dL) 1.6763.26 9.1968.03
a 5.2963.48
a
TC (mg/dL) 179.40634.40 238.00668.30
a 199.10648.30
e
VLDL-C (mg/dL) 16.8066.30 32.60617.40
a 26.40611.20
a
LDL-C (mg/dL) 114.80630.20 162.30665.00
a 133.00643.00
e
HDL-C (mg/dL) 48.30612.70 42.00611.30
d 39.80611.30
c
TG (mg/dL) 85.00631.40 161.50683.10
a 131.80656.20
a
ApoB (mg/dL) 91.40620.20 136.10650.20
a 115.10632.80
a
ApoE (mg/dL) 6.3261.79 10.6563.93
a 8.5362.49
a
ApoC-III (mg/dL) 9.0662.25 17.9167.52
a 16.8366.42
a
ApoC-III-HS (mg/dL) 6.0164.50 7.1563.90 10.0264.82
a
ApoC-III-HP (mg/dL) 3.8963.74 9.0165.42
a 5.7662.79
d
ApoC-III-R 1.8460.97 1.2161.16
d 2.1561.30
Age (years) 44.30613.10 55.10612.50
a 65.90610.60
a
Gender (Males) 30 (48%) 23 (65%) 23 (62%)
Gender (Females) 33 (52%) 12 (35%) 14 (38%)
Note:
CKD = chronic kidney disease before dialysis; HD = patients with kidney
disease on haemodialysis; TG = triglycerides; VLDL-C = very low density
lipoprotein-cholesterol; TC = total cholesterol;
LDL-C = low density lipoprotein-cholesterol; HDL-C = high density lipoprotein-
cholesterol;
ApoC-III-HS = apoC-III bound to HDL; ApoC-III-HP = apoC-III bound to apoB-
containing lipoproteins;
ApoC-III-R = ratio of apoC-III-HS/apoC-III-HP.
Two-tailed T-test with Satterthwaite adjustment were used to test mean
differences between controls and patient groups.
P-values reported are adjusted for multiplicity through the False Discovery Rate
(FDR) procedure.
Superscripts denote: a, p,0.0005; b, p,0.001; c, p,0.005; d, p,0.025; e,
p,0.05; no superscript=n.s.
doi:10.1371/journal.pone.0022360.t002
Figure 1. GC chromatograms. Fig. 1A. A typical GC chromatogram of separation of neutral lipid molecular species from a normal
subject. The separated FC, CE molecular species with C16, C18 and C20 fatty acyl groups and TG molecular species termed TG50, TG52, TG54 and
TG56 (the numbers represent the sum of the carbon chain lengths of the three fatty acyl groups of TG) are identified at the bottom of each peak.
Note the absence or undetectable of the peak TG48. Fig. 1B. An example of the GC chromatogram of separation of neutral lipid
molecular species from a HD patient. The separated molecular species are identified at the bottom of each peak. Note the presence of the peak
TG48 at retention time 17.699 min. in this renal patient. In case when TG48 was not completely separated from CE-C20, re-run with a reduced sample
application was carried out and complete separation could be achieved. Or, a vertical line drawing through the valley as this one, the results were
close to the former method.
doi:10.1371/journal.pone.0022360.g001
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different from controls. In CKD patients, the distribution of the
TG48 species shows relatively more monounsaturated TG48:1
and relatively less polyunsaturated TG48:3 than controls.
Therefore we can conclude that CKD patients have relatively
more SFAs and relatively less un-SFAs than controls.
Identification of the Fatty Acids in Various TG48 Forms by
MS/MS
To further our research we determined what fatty acids were
present in each form of these TG48 molecules. To characterize the
fatty acids comprising TG48:3, TG48:2, TG48:1 and TG48:0, we
performed MS/MS analysis of each TG48 form, corresponding to
ammonium adducted ions, 818.7, 820.7, 822.7 and 824.7 m/z.,
respectively. The MS/MS fragmentation of TG results in the
neutral losses of ammonia and a single fatty acid moiety and the
formation of a positively charged diacylglycerol (DG) ions. Results
are summarized in Table S1 (online table). To demonstrate an
example of the analysis, the four ammonium adducted TG48 ions
observed in the MS for patient A were each subjected to MS/MS
fragmentation to determine their DG
+1 fragments and constituent
fatty acids. MS ion at m/z=818.6, representing the TG48:3
molecules, was fragmented by MS/MS. Ammonia was lost to yield
TG
+1 at 801.7 m/z along with DG fragments and its product ions
were determined. Seven observed DG ions (Fig. not shown)
indicated that four different TG48:3 forms were present. LaOL
(laurate/oleate/linoleate, C12:0/C18:1/C18:2) was confirmed
based on the presence of ions 521.5 m/z, (DG1,2), 601.5 m/z
(DG2,3) and 519.4 m/z (DG1,3). The DG ion profile of MPLn
(myristate/palmitate/linoneneate, C14:0/C16:0/C18:3) was also
observed to consist of DG1,2 at 523.5 m/z, DG2,3 at 573.5 m/z
and DG1,3 at 545.5 m/z. Two other TG48:3 molecules were
found to be present. They were MPoL (M/palmitoleate/L,
C14:0/C16:1/C18:2), represented by DG1,2 at 521.5 m/z,
DG2,3 at 573.5 m/z, DG1,3 at 547.5 m/z and PoPoPo (C16:1/
C16:1/C16:1), in which all three DG forms produced an ion at
547.5 m/z. By the same approach, sample ion at 824.7 m/z
(TG48:0) was fragmented by MS/MS. Ammonia was lost to yield
TG
+1 at 807.7 m/z along with three DG fragments, DG
+1
1,2 at
523.5 m/z, DG
+1
2,3 at 579.5 m/z and DG
+1
1,3 at 551.5 m/z. The
ion at 551.5 was by far the most significant. This data indicated
the presence of two different TG48:0 molecules, PPP (tripalmitate,
Table 3. Correlations between oxidative stress marker R2, TG48 and lipid and lipoprotein variables.
Controls CKD HD
R2 R2 R2
r (95% C.I.) r (95% C.I.) r (95% C.I.)
TC 20.20 (20.42, 0.05) 20.17 (20.48, 0.17) 0.23 (20.11, 0.51)
VLDL-C 20.06 (20.31, 0.19) 20.38 (20.63, 20.05) 0.03 (20.29, 0.35)
LDL-C 20.15 (20.38, 0.10) 20.07 (20.39, 0.27) 0.31 (20.02, 0.58)
HDL-C 20.24 (20.46, 0.01) 0.05 (20.29, 0.37) 20.25 (20.53, 0.09)
TG 20.04 (20.28, 0.21)
c 20.38 (20.63, 20.05) 0.03 (20.30, 0.35)
ApoB 20.22 (20.45, 0.03) 20.17 (20.48, 0.17) 0.12 (20.21, 0.43)
ApoE 20.26 (20.48, 20.01) 20.02 (20.35, 0.32) 20.02 (20.34, 0.31)
ApoC-III 20.36 (20.56, 20.12)
e 20.41 (20.65, 20.09) 0.04 (20.29, 0.36)
ApoC-III-HS 0.14 (20.12, 0.37) 20.12 (20.43, 0.22) 20.04 (20.36, 0.29)
ApoC-III-HP 0.15 (20.10, 0.38) 20.41 (20.65, 20.09) 0.13 (20.20, 0.44)
ApoC-III-R 20.08 (20.32, 0.18) 0.13 (20.21, 0.44) 20.11 (20.42, 0.23)
TG48 TG48 TG48
r (95% C.I.) r (95% C.I.) r (95% C.I.)
TC 0.09 (20.16, 0.33) 0.00 (20.34, 0.33) 0.06 (20.27, 0.37)
VLDL-C 0.44 (0.22, 0.62)
c 0.78 (0.60, 0.88)
a 0.47 (0.17, 0.69)
d
LDL-C 0.08 (20.17, 0.32) 20.19 (20.49, 0.15) 20.06 (20.38, 0.27)
HDL-C 20.17 (20.40, 0.08) 20.25 (20.54, 0.09) 0.01 (20.31, 0.33)
TG 0.42 (0.19, 0.61)
c 0.79 (0.62, 0.89)
a 0.47 (0.17, 0.69)
d
ApoB 0.15 (20.10, 0.39) 0.16 (20.18, 0.47) 0.11 (20.22, 0.42)
ApoE 0.03 (20.22, 0.27) 0.29 (20.04, 0.57) 0.15 (20.18, 0.45)
ApoC-III 0.35 (0.11, 0.55)
d 0.49 (0.19, 0.71)
d 0.04 (20.29, 0.36)
ApoC-III-HS 20.05 (20.29, 0.20) 20.03 (20.36, 0.30) 20.10 (20.41, 0.23)
ApoC-III-HP 0.14 (20.12, 0.37) 0.55 (0.26, 0.74)
c 0.22 (20.11, 0.51)
ApoC-III-R 20.30 (20.51, 20.06)
e 20.42 (20.66, 20.11)
d 20.22 (20.51, 0.11)
Note:
Abbreviations used here are the same as in Tables 2.
FDR adjusted p-values, significant differences:
a, p,0.0005; b, p,0.001; c, p,0.005; d, p,0.025; e, p,0.05; no superscript=n.s.
doi:10.1371/journal.pone.0022360.t003
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C18:0). The PPP molecule was the predominant form, with all
three of its DG forms generating the same single MS/MS
fragment of 551.5. The MPS form was present at a lower level,
and its MS/MS fragmentation produced all three DG ions of
523.5, 579.5 and 551.5, with the ions at 523.5 and 579.5 being less
abundant, yet unique for the MPS form.
By the same approach, the fatty acids in TG48:2 (parent ion
820.7 m/z) and TG48:1 (parent ion 822.7 m/z) were also
identified. The results are shown in Table S1 (online table). The
fatty acids within the TG48 molecules were also determined for
patients B, C and D and two control subjects E and F. The fatty
acid composition of patient B was nearly identical to that of patient
A. The fatty acid composition of patients C, D and control E was
Table 4. Normalized intensities and percent composition of TG48 components in CKD, HD and controls.
Symbols m/z Mean ± SD Patients Mean ± SD Patients
with Intensity x 10
24 vs % vs
NH4
+1 Controls Controls
pp
CKD CKD
CE-C4 (I.S.) 474.3
TG48:3 818.8 151.8640.5 ,0.0005 11.1762.26 ,0.05
TG48:2 820.6 353.2644.8 ,0.0005 26.2662.37 NS
TG48:1 822.6 576.8638.4 ,0.0005 43.0163.33 ,0.001
TG48:0 824.7 265.1655.3 ,0.0005 19.5662.22 NS
HD HD
TG48:3 818.8 77.1652.6 ,0.01 13.1862.99 NS
TG48:2 820.6 177.56133.2 ,0.01 28.1365.13 NS
TG48:1 822.6 277.96230.9 ,0.01 38.86611.16 NS
TG48:0 824.7 122.6690.5 ,0.005 19.8363.80 NS
Controls Controls
TG48:3 818.8 22.5614.6 16.0163.55
TG48:2 820.6 46.1628.6 32.8166.75
TG48:1 822.6 42.1620.5 32.6562.92
TG48:0 824.7 19.5610.6 18.47611.51
Note: 4 CKD patients, 4 HD patients and 6 healthy controls were randomly selected for this study.
doi:10.1371/journal.pone.0022360.t004
Figure 2. Mass spectrometry of TG48 species. Mass spectrometry of plasma neutral lipids of a patient was analyzed as described in the
Methods. TG48 species were zoomed at 815–830 m/z. Peaks were identified based on their m/z values matched to the known compounds which
were labeled on top or the right side of the peaks. Symbols used: TG48:3, three double bonds present in TG48, i.e. tripalmitolein or
tripalmitoleylglycerol; TG48:2, two double bonds present in TG48, i.e. dipalmitoleyl-palmitylglycerol; TG48:1, one double bond present in TG48, i.e.
dipalmity-palmitoleylglycerol; TG48:0, saturated TG48, i.e. tripalmitate; In the presence of NH4
+1, saturated TG48 was identified at m/z 824.8. Three
unsaturated TG48 were identified at m/z 818.7, 820.8 and 822.8.
doi:10.1371/journal.pone.0022360.g002
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control F was identical to that of patient B. All results are listed in
Table S1 (online table).
It is interesting to note that the compositions of the fatty acids in
TG48 in these six subjects are identical or nearly identical. Further
exploration with additional patients or controls was thought
unnecessary. We have now demonstrated that TG48 is a SFA-rich
TG species in both patients and normal subjects. The difference
between patients and controls is the quantity. Patients have many
fold higher levels of SFAs than controls. Also CKD patients have
lower percent polyunsaturated TG48:3 and higher percent
monounsaturated TG48:1 than controls. When TGs’ are partially
hydrolysed in vivo, large amount of saturated DGs’ are
accumulated. Saturated DGs’ and SFAs are inflammatory [18].
Discussion
In this study, we have clearly established that TG48 is a SFA-
rich TG species. Since SFAs are inflammatory [18], their
increased levels reflect increased inflammation in renal patients.
The association between SFAs and inflammation and their
mechanisms has been well studied. SFAs inhibit the activation of
insulin receptor substrate 1, which causes insulin resistance and
contributes to metabolic syndrome [18]. This inhibition could
occur in insulin-sensitive cells like white adipose tissue, muscle,
heart and liver [23]. SFAs cause the activation of the mitogen-
activated protein kinases and subsequent induction of inflamma-
tory genes in white adipose tissue, immune cells, and mitotubes.
SFAs decrease adiponectin production, which decreases the
oxidation of glucose and fatty acids [18]. SFAs cause recruitment
of immune cells, such as macrophages, neutrophils, and bone
marrow-derived dendritic cells to white adipose tissue and muscle.
Palmitate but not linoleate activates macrophages [24] which lead
to the production of cytokine interleukin-6 in coronary artery
endothelial cells and coronary artery smooth muscle cells [25].
Excess palmitate causes white adipose tissue dysregulation [26]. It
also increases inflammation and apoptosis through oxidative or
endoplasmic reticulum stress and generation of reactive oxygen
species. Oleate co-supplementation blocks palmitate-mediated
suppression of b-oxidation, insulin sensitivity, and DG accumu-
lation. These experiments suggest that SFAs are inflammatory,
while the unsaturated fatty acids are not [18]. Furthermore, higher
polyunsaturated fatty acids, such as eicosapentaenoic and
docosahexaenoic, have anti-inflammatory effects by inhibiting
cyclooxygenase 2 and demonstrate the ability to reduce plasma
concentrations of C-reactive protein (CRP), tumor necrotizing
factor-a and interleukin-6 [27]. Interestingly, the carbon flux from
a carbohydrate diet is converted to palmitate in the liver during
endogenous lipogenesis [28]. Thus, a diet rich in carbohydrates
can also be inflammatory.
As shown in Table 2, TG increased in patients with HD and
CKD relative to levels in control subjects. TG48 also increased
from controls to HD and to CKD. However, TG48/TG ratios (or
TG48%/TG) are not the same for the three groups. TG48%/TG
significantly (p,0.0005) increased from controls (1.7%62.9%) to
HD (4.2%62.6%) and to CKD (5.2%63.2%). This means that
when TG is increased, TG48 is disproportionately increased. This
results in the longer-chain TG species (TG50+TG52+TG54+
TG56), increased less proportionally, because the sum of TG48+
TG50+TG52+TG54+TG56 equals TG.
As shown by Byrdwell [21], the longer the carbon chain length
of the fatty acids, the higher the unsaturation of the TG. Thus,
TG48 possesses relatively higher number of SFAs than those of
TG50, TG52, TG54 and TG56. Therefore, increasing TG results
in increasing more of TG48, thus, increasing more of SFAs and
concomitantly increasing inflammation.
We observed that subjects with increased TG without renal
disease also have increased TG48 (unpublished data). So the
presence of measurable TG48 by GC is not a unique marker for
renal disease. It is actually a reflection of the increased SFAs,
therefore a reflection of increased inflammation. Indeed, hyper-
triglyceridemia is also known to be associated with increased
inflammation.
The presently established link between OS/inflammation and
apoC-III bound to apoB-containing lipoproteins is further
enhanced by the recently reported findings [13] that apoC-III,
or its corresponding apoB-containing lipoproteins, were also
proinflammatory as demonstrated by increasing endothelial cell
expression of vascular and intercellular cell adhesion molecules
and recruitment of monocytic cell. It is not surprising to see that
TG48 is well correlated with apoC-III. Is there a cause- effect
relationship between apoC-III and TG48? We are not certain. We
may rationalize that when apoC-III is increased, TG would
increase, since over expression of apoC-III gene could cause
hypertriglyceridemia [29]. Our data indicate that when TG is
increased, TG48 is increased more than the other TG molecular
species. This implies that increased apoC-III could cause the
increase of TG48 and thus increased levels of SFA. On the other
hand, a diet rich in SFAs might increase TG. Would increased TG
cause the increase of apoC-III? There might be such a possibility.
However, more research is needed to answer this question
unequivocally.
Inflammation causes the generation of reactive oxygen species
[18]. This may be why inflammation is closely associated with OS
and vice versa. Several studies support a link between OS and
inflammation in atherogenesis [30,31]. Our data showing that OS
index R2 correlated with TG48 may support this notion.
A number of studies have suggested that increased OS in
association with inflammation contributes significantly to the
accelerated kidney dysfunction and its consequential cardiovascu-
lar morbidity and mortality [1–12]. Most of the previously
described procedures to access OS are rather complicated and
time consuming [2–7,9,12,32–35]; however, our presently de-
scribed method does not require treatment with chemical reagents,
monoclonal antibodies, incubation, isolation of lipid classes or
transesterification and therefore, provide a direct and very useful
simplification. The main advantage of the GC method besides
simplicity and speed is high reproducibility. R2 values have shown
that a combination of OS and the levels of apoC-III in a binary
system predict the risk for atherosclerosis in normolipidemic and
hypertriglyceridemic subjects [36]. Cholesteryl ester ratio method
has also been successfully used to monitor the delay of OS
recovery in patients with diabetic ketoacidosis after correction of
ketoacidosis with insulin [37]. Inflammation levels have been most
frequently measured by CRP [38] and interleukin-6 [25,27]. Both
of these proteins are the results of inflammation. In contrast, SFAs
measured by TG48 are the causes of inflammation.
Our data show that the inflammation measured by TG48 is
correlated with TG, not CE. Since TG48 is part of the total TG,
in general, the higher the TG, the higher the TG48, thus the
higher the SFA and the higher the inflammation. Indeed, higher
TG is associated with higher OS, as also shown by the CE-ratio
method, but TG alone does not represent TG48 because the
TG48/TG ratio is not a constant among different subjects.
Abnormalities of lipid and apolipoprotein profiles of CKD and
HD patients confirmed and extended the results of our previous
studies [15,16]. Moreover, based on correlation coefficients
between R2 and especially, TG48 and lipid, apolipoprotein, and
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is highly correlated with the concentrations of TG and VLDL-C,
moderately correlated with apoC-III bound to apoB-containing
lipoproteins, and weakly with apoC-III, but not with TC, LDL-C
nor with HDL-C. These results suggest that the high inflammation
of renal patients stems more from TG-rich lipoproteins, not CE-
rich apoB lipoproteins. The highly selective correlation of infla-
mmation with TG or apoC-III-containing apoB lipoproteins, but
not with cholesterol-rich apoB lipoproteins, was confirmed by the
results of multivariate regression analysis showing a stronger
relationship between TG48 and VLDL-C over LDL-C (15 times
stronger for VLDL-C than that for LDL-C as shown by the
equation #1).
Results from our study and those of other laboratories have
already shown the significant role played by apoC-III bound to
apoB-containing lipoproteins in the formation and progression of
atherosclerotic lesion [39]. Specifically, renal insufficiency result-
ing in elevated apoC-III, or LpB:C-III, presumably via insulin
resistance triggers the chain of inflammatory events [40]. Taken
together, findings of the present study suggest that TG-rich apoC-
III-containing apoB lipoproteins are linked to inflammation, while
TC-rich apoB lipoproteins are not. It remains to be determined
whether there are differences in the degree of inflammation
between apolipoprotein-defined apoC-III-containing lipoproteins,
including LpB:C, LpB:C:E and LpA-II:B:C:D:E particles.
The use of the TG48 marker revealed that HD patients had
significantly lower inflammation and partially reduced levels of
lipoprotein variables than CKD patients, suggesting a beneficial
effect of haemodialysis that alleviates the uremic intoxication but
cannot eliminate the underlying metabolic disturbance that
persists during dialysis.
It has been observed that increased OS is already prevalent in
CKD patients before dialysis [5,41]. Our findings on increased
OS/inflammation in renal patients are in agreement with the
literature reports [2–12,33]. This is the first report using TG48 for
measuring SFAs and inflammation. This is also the first report to
relate SFAs and inflammation with lipids and lipoproteins, and
particularly, with apoC-III and apoC-III-containing apoB lipo-
proteins.
Conclusions
The major finding of this study is the recognition of TG48 as a
new inflammatory factor characterized by the occurrence of
inflammatory saturated fatty acids. The levels of TG48 had been
found to be elevated in patients with chronic renal disease in
comparison with those of normolipidemic subjects. The TG48
levels were correlated with the levels of TG, VLDL-C, apoC-III
and apoC-III bound to apoB-containing lipoprotein subclasses,
but not with TC, LDL-C and HDL-C in kidney patients.
Furthermore TG48 is also correlated with oxidative stress. The
well established dual role of apoC-III in inflammation and
atherogenesis in combination with oxidative stress and inflamma-
tory TG48 should be considered as severe risk factors for
atherogenesis in chronic kidney disease. Further studies are
needed to establish the occurrence of similar risk factors for
atherogenesis in other dyslipoproteinemics.
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